| Similar Articles |
|---|
 |
The Motley Fool
November 27, 2006
Brian Lawler |
Roche Says Goodbye to PDL The larger pharmaceutical drops out of daclizumab development. Investors, take note.   |
The Motley Fool
April 14, 2008
Brian Lawler |
PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business. |
The Motley Fool
November 12, 2007
Brian Lawler |
What's New at PDL BioPharma? The past few volatile months are reflected in the third-quarter results from PDL BioPharma. The future, however, may be smoother. Investors, take note. |
The Motley Fool
January 26, 2005
Charly Travers |
Protein Design Muscles Up Biotech company buys itself a bigger future. The company announced that it had acquired privately held ESP Pharma for $300 million cash and $175 million stock. |
The Motley Fool
February 27, 2007
Brian Lawler |
PDL Keeps Us Waiting PDL BioPharma announces its year-end financial results. Investors, take note. |
The Motley Fool
August 29, 2007
Brian Lawler |
PDL Lands in a Hazard The biopharma announces a dramatic shift following the failure of its lead drug. Shares of PDL are down only 19% this morning, presumably because the thought of a leaner and thriftier PDL with its royalty-generating potential is a welcome relief to some investors. |
The Motley Fool
December 18, 2007
Brian Lawler |
PDL Liquidation Sale Begins PDL BioPharma's sale of a chemotherapy drug indicates it could recoup what it paid for ESP Pharma. Investors, take note. |
The Motley Fool
July 14, 2005
Charly Travers |
Dueling Fools: Protein Design Labs Bull Rebuttal This biotech's tomorrow is coming today. The company is a clear buy at its current market cap near $2 billion. |
The Motley Fool
April 28, 2011
Brian Orelli |
Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable. |
The Motley Fool
April 27, 2007
Brian Lawler |
PDL Gets the Go-Ahead Signal The biopharma moves its lead compound into phase 3 testing. Investors, take note. |
The Motley Fool
May 30, 2008
Brian Lawler |
PDL Shakeup Lifts Shares Shares of PDL BioPharma rise after a longtime board member, currently the company's interim CEO, departs. |
The Motley Fool
August 2, 2007
Brian Lawler |
PDL Minds Its Mild Manners The biopharma announces placid second-quarter results -- investors, take note. |
The Motley Fool
February 6, 2008
Brian Lawler |
PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note. |
The Motley Fool
May 7, 2008
Brian Lawler |
PDL Delivers a Dividend The drugmaker's investors get a hefty payout. |
The Motley Fool
March 5, 2008
Brian Lawler |
PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring. |
The Motley Fool
March 15, 2005
Charly Travers |
PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note. |
The Motley Fool
August 5, 2005
Charly Travers |
No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders. |
The Motley Fool
October 15, 2007
Brian Lawler |
PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note. |
The Motley Fool
March 16, 2007
Brian Lawler |
PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note. |
The Motley Fool
September 26, 2007
Brian Lawler |
Shareholders Pile On Against PDL Another large shareholder has come out against the status quo at PDL BioPharma. Management resignations seen as necessary by those wanting to sell or break apart the biopharma. |
The Motley Fool
July 14, 2005
Charly Travers |
Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders. |
The Motley Fool
August 21, 2007
Brian Lawler |
Change of Pace at PDL Shares of PDL BioPharma have risen more than 10% since CEO McDade announced yesterday that he would resign by the end of the year. |
The Motley Fool
September 28, 2007
Brian Lawler |
Interview With PDL Co-Founder Cary Queen PDL BioPharma has generated much investor activism against its current management team, with some investors calling for a sale of the drugmaker. In this interview, co-founder Cary Queen discusses the current state of affairs. |
The Motley Fool
September 24, 2007
Brian Lawler |
Seismic Shifts at PDL No matter what its hedge fund owner, Third Point, decides it wants to do with PDL, one thing is clear: A year from now, PDL BioPharma will not be the same drugmaker that it is today. Investors, take note. |
The Motley Fool
August 18, 2008
Brian Lawler |
When Breaking Up Isn't Hard to Do PDL BioPharma and Enzon are the latest biotechs looking to spin off parts of their business. |
The Motley Fool
December 7, 2011
Dan Caplinger |
Has PDL BioPharma Become the Perfect Stock? Having moved from special dividends to a pure regular-dividend payout has improved income visibility for shareholders. |
The Motley Fool
August 21, 2008
Brian Lawler |
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. |
The Motley Fool
July 9, 2004
Charly Travers |
Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL. |
The Motley Fool
June 14, 2007
Brian Lawler |
Dueling Fools: GlaxoSmithKline Bull Rebuttal Investors who think this pharma's market cap is too large would be missing out on the chance to own one of the best-run companies in the most exciting industry. |
The Motley Fool
January 31, 2008
Brian Lawler |
Don't Forget Roche Roche, the largest biopharma, by market capitalization, had a terrific 2007. Since it is not publicly listed on the major U.S. stock exchanges, the company never gets its fair share of attention. |
The Motley Fool
May 3, 2005
Charly Travers |
PDL's Well-Stocked Pipeline A broad drug portfolio makes this biotech, Protein Design Labs, a long-term winner. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
January 29, 2008
Brian Lawler |
Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected. |
The Motley Fool
May 18, 2011
Brian Orelli |
If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship. |
The Motley Fool
August 3, 2005
Charly Travers |
Biotech's Big Deal The market is pleased with the partnership between Protein Design Labs and Biogen IDEC. |
The Motley Fool
July 10, 2008
Brian Lawler |
Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks. |
The Motley Fool
November 2, 2004
Charly Travers |
Just the Medicine for PDL Losses are shrinking as drug royalties spur strong revenue growth. |
The Motley Fool
December 11, 2006
Brian Lawler |
Roche's Early Present to Halozyme Assuming it works, Enhanze may be a platform technology that could be applied across a wide range of injected products. Roche isn't exactly betting the farm on its success, though, with only $20 million of guaranteed up-front money. Investors, take note. |
The Motley Fool
October 17, 2006
Brian Lawler |
Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at. |
The Motley Fool
February 25, 2005
Charly Travers |
Protein Design Labs' Future A look ahead to a transitional year -- and how much the ESP Pharma acquisition will boost revenues -- coming Monday. |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
The Motley Fool
May 2, 2007
Brian Lawler |
Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note. |
The Motley Fool
May 5, 2006
Stephen D. Simpson |
Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note. |
The Motley Fool
February 22, 2007 |
PDL Biopharma's Fair Q4: Fool by Numbers The pharmaceutical released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
December 13, 2004
Charly Travers |
PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success. |
The Motley Fool
August 14, 2008
Brian Lawler |
Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid. |
The Motley Fool
March 28, 2005
Charly Travers |
Stock Madness 2005: Protein Design Labs vs. Yahoo! Two very different Rule Breakers face off in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness. |
The Motley Fool
August 29, 2008
Brian Lawler |
Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity? |
The Motley Fool
October 13, 2010
Jordan DiPietro |
3 Sinking Stocks for Savvy Investors These three socks may be ready to climb. |
